Advances in Papillary Thyroid Cancer Research
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 6294
Special Issue Editor
Special Issue Information
Dear Colleagues,
Papillary thyroid cancer (PTC) accounts for more than 80% of all thyroid carcinomas, and patients face a good prognosis with a 10-year overall survival exceeding 90%. The incidence is increasing, but still considered low compared to other cancers; however, due to the excellent prognosis, the prevalence is relatively high. Curative treatment consists of thyroid surgery, total thyroidectomy or lobectomy in some cases, and radioactive iodine treatment when implied. After a thyroidectomy, patients are dependent on lifelong thyroid hormone supplementation. Because thyroid-stimulating hormone (TSH) stimulates cancer cells, patients usually receive levothyroxine in doses to suppress TSH. This induces a state of iatrogenic subclinical hyperthyroidism, and a more aggressive suppression therapy reduces the risk of recurrence, but might give side-effects which could reduce health-related quality of life (HRQoL).
These sometimes life-long treatments might influence a large number of patients negatively, and it is therefore of great importance not to overtreat patients. BRAF and TERT promoter mutations are common in thyroid cancer, and are often carried over from primary tumors to lymph node and distant metastases, and the co-occurrence of these two mutational events in PTC has been found to be intimately coupled to aggressive tumor features. It is also known that tumors exhibiting BRAF V600E or TERT promoter mutations are less likely to spawn iodine avid metastases, and these aberrations are strongly associated with poorer patient outcomes.
In this Special Issue we would like to discuss further how we can individualize treatment for PTC patients depending on the specific characteristics of the tumor, and from that decide which treatment will be most efficient. In addition, new treatment modalities focusing on PTC subgroups or approaches for small indolent cancers with a “watch and wait” approach will be of interest.
Dr. Catharina Ihre Lundgren
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- papillary thyroid cancer
- prognosis
- surgery
- radioiodine therapy
- suppression treatment
- complications
- HRQoL
- BRAF
- TERT
